Biocon: Launching a New Cancer Drug in India

Below are the available bulk discount rates for each individual item when you purchase a certain amount

Register as a Premium Educator at hbsp.harvard.edu, a course, and save your students up to 50% with your academic discount.

Publication Date:
August 28, 2007

Industry:
Professional Services

Source:
Harvard Business School

Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and mix decisions relating to the launch of BioMAb, a new cancer drug in India.

Copyright © 2021 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.

Biocon: Launching a New Cancer Drug in India

Research & References of Biocon: Launching a New Cancer Drug in India|A&C Accounting And Tax Services
Source

Leave a Reply